Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed.
作者信息
Waller P C, Wood S M, Breckenridge A M, Rawlins M D
机构信息
Medicines Control Agency, London.
出版信息
Br J Clin Pharmacol. 1994 Aug;38(2):93. doi: 10.1111/j.1365-2125.1994.tb04329.x.
Abstract
摘要
相似文献
1
Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed.为什么需要已上市药品安全评估（SAMM）指南。
Br J Clin Pharmacol. 1994 Aug;38(2):93. doi: 10.1111/j.1365-2125.1994.tb04329.x.
2
Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993).公司资助的上市药品安全性评估指南（SAMM指南）。药品控制局、药品安全委员会、皇家全科医师学院、英国医学协会和英国制药工业协会（1993年11月）
Br J Clin Pharmacol. 1994 Aug;38(2):95-7. doi: 10.1111/j.1365-2125.1994.tb04330.x.
3
A retrospective survey on the safety of Replenine, a high-purity factor IX concentrate.一项关于高纯度凝血因子IX浓缩剂Replenine安全性的回顾性调查。
Pharmacoepidemiol Drug Saf. 2004 Mar;13(3):187-95. doi: 10.1002/pds.911.
4
Probing the safety of central venous catheters.
Am J Nurs. 1993 May;93(5):72, 75-6.
5
Review of company postmarketing surveillance studies.公司上市后监测研究综述。
BMJ. 1992 Jun 6;304(6840):1470-2. doi: 10.1136/bmj.304.6840.1470.
6
FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.美国食品药品监督管理局（FDA）准备收紧关于医药产品未经批准用途信息的行业传播指南。
Gastroenterology. 2008 Apr;134(4):905. doi: 10.1053/j.gastro.2008.02.070.
7
Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.欧洲、加拿大和美国针对后续生物制品市场授权的立法举措。
Curr Opin Drug Discov Devel. 2010 Mar;13(2):247-56.
8
The Japanese Postmarketing Adverse Event Relief System: A Confluence of Regulatory Science, the Legal System, and Clinical Pharmacology.日本上市后不良事件救济系统：监管科学、法律体系与临床药理学的融合
Clin Pharmacol Ther. 2017 Aug;102(2):277-282. doi: 10.1002/cpt.537. Epub 2016 Dec 7.
9
Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.临床药理学：药物研发与药物警戒中的特殊安全性考量
Drug Saf. 2004;27(8):535-54. doi: 10.2165/00002018-200427080-00006.
10
Proposed amendments to the medical devices Directives.对医疗器械指令的拟议修订。
Med Device Technol. 2006 Jan-Feb;17(1):22-5.
引用本文的文献
1
Design issues for drug epidemiology.药物流行病学的设计问题
Br J Clin Pharmacol. 2000 Nov;50(5):419-25. doi: 10.1046/j.1365-2125.2000.00289.x.
2
Good practice in the postmarketing surveillance of medicines.
Pharm World Sci. 1997 Aug;19(4):186-90. doi: 10.1023/a:1008610722972.
本文引用的文献
1
New horizons in post-marketing surveillance.上市后监测的新视野。
Health Trends. 1993;25(3):83.
2
Review of company postmarketing surveillance studies.公司上市后监测研究综述。
BMJ. 1992 Jun 6;304(6840):1470-2. doi: 10.1136/bmj.304.6840.1470.
Zotero 插件